Open Access
Issue
Published:
03 April 2023
Establishment of a donor pig for xenotransplantation clinical trials based on the principle of Changsha Communiqué
)
Download citation
306
Views
17
Downloads
0
Crossref
N/A
WoS
0
Scopus
N/A
CSCD
Xenotransplantation is a potential way to reduce the shortage of the needed organ grafts for the end‐stage disease. Immune rejection, physiological incompatibility and bio‐safety are the most critical issues.
To ensure the safety and efficacy of gene editing, second‐ and third‐generation sequencing technologies have allowed us to obtain a clearer genetic background of donor pigs for xenotransplantation. Based on the Changsha Communiqué, the local DPF‐excluded lists and DPF donor facility were established in Changsha, China. A pig‐to‐human islet clinical trial was conducted and overseen by the respective Chinese governmental agency.
The DPF standards for pig husbandry eliminated specific pathogens in donor pigs. We have established a PERV‐C free, genetic information clean, DPF donor for xenotransplantation. A clinical trial of ten adult patients (9M:1F) with type 1 diabetes who received DPF porcine islet xenotransplantation via the portal vein were performed. Clinical accepted immunosuppressant drugs and autologous Treg were used for controlling immune rejection. No cross‐species infection events occurred in this trial, and importantly, no cross‐species transmission of PERV was found.
Xenotransplantation is a pioneer study and safety is the most important issue. The fundamental principles for establishing xenotransplantation donor pigs should follow the Changsha Communiqué (2008), the second WHO consultation,and the 2018 Changsha Communiqué which would finally help reducing the risks of xenotransplantation.
menu
Establishment of a donor pig for xenotransplantation clinical trials based on the principle of Changsha Communiqué
)
Abstract
Xenotransplantation is a potential way to reduce the shortage of the needed organ grafts for the end‐stage disease. Immune rejection, physiological incompatibility and bio‐safety are the most critical issues.
To ensure the safety and efficacy of gene editing, second‐ and third‐generation sequencing technologies have allowed us to obtain a clearer genetic background of donor pigs for xenotransplantation. Based on the Changsha Communiqué, the local DPF‐excluded lists and DPF donor facility were established in Changsha, China. A pig‐to‐human islet clinical trial was conducted and overseen by the respective Chinese governmental agency.
The DPF standards for pig husbandry eliminated specific pathogens in donor pigs. We have established a PERV‐C free, genetic information clean, DPF donor for xenotransplantation. A clinical trial of ten adult patients (9M:1F) with type 1 diabetes who received DPF porcine islet xenotransplantation via the portal vein were performed. Clinical accepted immunosuppressant drugs and autologous Treg were used for controlling immune rejection. No cross‐species infection events occurred in this trial, and importantly, no cross‐species transmission of PERV was found.
Xenotransplantation is a pioneer study and safety is the most important issue. The fundamental principles for establishing xenotransplantation donor pigs should follow the Changsha Communiqué (2008), the second WHO consultation,and the 2018 Changsha Communiqué which would finally help reducing the risks of xenotransplantation.
References(21)
Porrett PM, Orandi BJ, Kumar V, Houp J, Anderson D, Cozette Killian A, et al. First clinical‐grade porcine kidney xenotransplant using a human decedent model. Am J Transplant. 2022;22(4):1037–53. https://doi.org/10.1111/ajt.16930
Sade RM, Mukherjee R. Ethical issues in xenotransplantation: the first pig‐to‐human heart transplant. Ann Thorac Surg. 2022;113(3):712–4. https://doi.org/10.1016/j.athoracsur.2022.01.006
Griffith BP, Goerlich CE, Singh AK, Rothblatt M, Lau CL, Shah A, et al. Genetically modified porcine‐to‐human cardiac xenotransplantation. N Engl J Med. 2022;387(1):35–44. https://doi.org/10.1056/NEJMoa2201422
Lunney JK, Van Goor A, Walker KE, Hailstock T, Franklin J, Dai C. Importance of the pig as a human biomedical model. Sci Transl Med. 2021;13(621):eabd5758. https://doi.org/10.1126/scitranslmed.abd5758
WHO. Second WHO global consultation on regulatoryrequirements for xenotransplantation clinical trials. Geneva,Switzerland: WHO; 2011. https://apps.who.int/iris/handle/10665/341817
Gazda LS, Collins J, Lovatt A, Holdcraft RW, Morin MJ, Galbraith D, et al. A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials. Xenotransplantation. 2016;23(6):444–63. https://doi.org/10.1111/xen.12277
Onions D, Cooper DKC, Alexander TJL, Brown C, Claassen E, Foweraker JE, et al. An approach to the control of disease transmission in pig‐to‐human xenotransplantation. Xenotransplantation. 2000;7(2):143–55. https://doi.org/10.1034/j.1399-3089.2000.00047.x
Hawthorne WJ, Cowan PJ, Bühler LH, Yi S, Bottino R, Pierson RN 3rd, et al. Third WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials, Changsha, Hunan, China December 12–14, 2018: “The 2018 Changsha Communiqué”: the 10‐year Anniversary of The International Consultation on Xenotransplantation. Xenotransplantation. 2019;26(2):e12513. https://doi.org/10.1111/xen.12513
Dixon LK, Sun H, Roberts H. African swine fever. Antiviral Res. 2019;165:34–41. https://doi.org/10.1016/j.antiviral.2019.02.018
Spizzo T, Denner J, Gazda L, Martin M, Nathu D, Scobie L, et al. First update of the international xenotransplantation association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Chapter 2a: source pigs—preventing xenozoonoses. Xenotransplantation. 2016;23(1):25–31. https://doi.org/10.1111/xen.12223
Cowan PJ, Ayares D, Wolf E, Cooper DKC. First update of the international xenotransplantation association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Chapter 2b: genetically modified source pigs. Xenotransplantation. 2016;23(1):32–7. https://doi.org/10.1111/xen.12224
Fishman JA, Scobie L, Takeuchi Y. Xenotransplantation‐associated infectious risk: a WHO consultation. Xenotransplantation. 2012;19(2):72–81. https://doi.org/10.1111/j.1399-3089.2012.00693.x
Guo F, Xing X, Hawthorne WJ, Dong Q, Ye B, Zhang J, et al. Characterization of PERV in a new conserved pig herd as potential donor animals for xenotransplantation in China. Virol J. 2014;11(1):212. https://doi.org/10.1186/s12985-014-0212-1
Wynyard S, Nathu D, Garkavenko O, Denner J, Elliott R. Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. Xenotransplantation. 2014;21(4):309–23. https://doi.org/10.1111/xen.12102
Matsumoto S, Tan P, Baker J, Durbin K, Tomiya M, Azuma K, et al. Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc. 2014;46(6):1992–5. https://doi.org/10.1016/j.transproceed.2014.06.008
Robbins HA, Clarke CA, Arron ST, Tatalovich Z, Kahn AR, Hernandez BY, et al. Melanoma risk and survival among organ transplant recipients. J Invest Dermatol. 2015;135(11):2657–65. https://doi.org/10.1038/jid.2015.312
Liao JB, Fisher CE, Madeleine MM. Gynecologic cancers and solid organ transplantation. Am J Transplant. 2019;19(5):1266–77. https://doi.org/10.1111/ajt.15292
Chen LN, Spivack J, Cao T, Saqi A, Benvenuto LJ, Bulman WA, et al. Characteristics and outcomes of lung cancer in solid organ transplant recipients. Lung Cancer. 2020;146:297–302. https://doi.org/10.1016/j.lungcan.2020.06.018
Watson AL, Carlson DF, Largaespada DA, Hackett PB, Fahrenkrug SC. Engineered swine models of cancer. Front Genet. 2016;7:78. https://doi.org/10.3389/fgene.2016.00078
Hawthorne WJ, Cowan PJ, Buhler L, Wolf E. International standards and guidelines for xenotransplantation. Nature Biotechnol. 2021;39(12):1501–2. https://doi.org/10.1038/s41587-021-01148-3
Publication history
Copyright
Acknowledgements
This project was supported by grants from the National Key Research and Development Program of China (Grant No. 2019YFA0110703), the National Natural Science Foundation of China (Grant No. 82272102), and the Natural Science Foundation of Hunan Province, China (Grant No. 2021JJ31018).
Rights and permissions
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
FEEDBACK 
TOP